Compare AbCellera Biologics Inc (ABCL) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Emerson Electric Co. — how do they compare? AbCellera Biologics Inc trades at $9.2 (market cap $2.99B), while Emerson Electric Co. trades at $165.85 (market cap $91.69B). The key difference: Emerson Electric Co. is far larger — about 30.7× AbCellera Biologics Inc's market cap, and Emerson Electric Co. pays a 1.35% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EMR | |
|---|---|---|
Market Cap | $2.99B | $91.69B |
Sector | Health | Industrials |
52-Week High | $9.76 | $164.38 |
52-Week Low | $2.78 | $123.30 |
Enterprise Value | $2.58B | $102.77B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Emerson Electric (EMR) trades at $158.69, up 0.27% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $1.71 exceeding expectations, supported by 7% revenue growth and expanding margins. Recent acquisition of Glue Inc. enhances AI capabilities while dividend payments provide shareholder returns.
Outlook remains positive with raised 2026 guidance and $171.33 consensus price target offering 8% upside. Key risks include valuation at 36x P/E and cyclical exposure to industrial markets. Institutional support remains strong with 53.7% buy ratings, though RSI levels suggest potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
